Table 2. Scoring data from Wnt5a, AR, VEGF and Ki-67 immunostained cores from benign and cancer tissues in duplicates mounted in a TMA.
| Wnt5a | AR | VEGF | Ki-67 | |||||
| Score | Benign | Cancer | Benign | Cancer | Benign | Cancer | Benign | Cancer |
| 0 | 60 (15) | 14 (4) | 6 (1.5) | 2 (0.5) | 14 (3) | 16 (5) | 55 (14.2) | 21 (5.3) |
| 1 | 205 (50) | 53 (14) | 186 (45.6) | 126 (30.1) | 184 (46) | 80 (23) | 323 (83.2) | 341 (85.5) |
| 2 | 123 (30) | 162 (44) | 165 (40.4) | 179 (42.7) | 175 (44) | 180 (52) | 9 (2.3) | 33 (8.3) |
| 3 | 19 (5) | 141 (38) | 51 (12.5) | 112 (26.7) | 29 (7) | 72 (21) | 1 (0.2) | 4 (1) |
| Total | 407 (100) | 370 (100) | 408 (100) | 419 (100) | 402 (100) | 348 (100) | 388 (100) | 431 (100) |
| Missing | 57 | 94 | 56 | 45 | 62 | 116 | 76 | 65 |
| Total | 464 | 464 | 464 | 464 | 464 | 464 | 464 | 464 |
| p-value | <0.0001 | <0.0001 | <0.0001 | <0.0001 | ||||
Scoring is based on arbitrary units with 0 representing no staining, 1 as weak staining, 2 as moderate staining and 3 as strong staining. For Ki-67 the percentage of nuclear positivity was scored as 0 (0–1% positive nuclei), 1 (1–3% positive nuclei), 2 (4–10% positive nuclei) and 3 (11–20% positive nuclei). The p values at the bottom row of the table indicate statistically significant differences between benign and cancer samples from same patient when Wilcoxon rank sum tests were performed. The values in the brackets represent number of patients (%) based on the highest score from each individual duplicate. Patients who underwent radiation therapy and/or hormonal therapy before radical prostatectomy were excluded from the IHC analysis.